G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

World News: . []

RESEARCH TRIANGLE PARK, N.C., May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex (fulvestrant) will be presented in a poster session on June 2 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago, IL. These data showed promising safety and tolerability when G1T38 was dosed continuously as a treatment for people with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer.

G1T38 is an oral CDK4/6 inhibitor with broad therapeutic potential in many forms of cancer and may serve as backbone therapy for multiple combination regimens.

“The combination of G1T38 and Faslodex has been well tolerated in this Phase 1b clinical trial, with no treatment-related serious adverse events reported. CDK4/6 inhibition can cause dose-limiting neutropenia that may require a treatment holiday. Importantly, chronic use of G1T38 in this trial resulted in dose-dependent decreases in absolute neutrophil counts that plateaued after four to five weeks of therapy. This allowed for continuous dosing of G1T38 without a drug holiday,” said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. “The dose escalation portion of this clinical trial is ongoing, and we are encouraged by the early safety, tolerability and efficacy findings that support the continued development of G1T38 as a potential best-in-class oral CDK4/6 inhibitor.”

Details on the presentation are listed below and are also available on the 2018 ASCO Annual Meeting website: .

For more information about the 2018 ASCO Annual Meeting, please visit .

G1T38 is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with Faslodex for people with ER+, HER2- breast cancer (), and a trial in combination with Tagrisso for people with EGFR-mutant non-small cell lung cancer ().

Faslodex has also been licensed for use with CDK4/6 inhibitors, palbociclib (in the U.S., EU and several other markets) and abemaciclib (in the U.S. only) for the treatment of women with ER+, HER2- advanced breast cancer, whose cancer has progressed after endocrine therapy. In Japan, Faslodex is also approved for use in combination with any CDK4/6 inhibitor.

G1 is based in Research Triangle Park, NC. For additional information, please visit  and follow us on Twitter @G1Therapeutics.

More news and information about G1 Therapeutics

Published By:

Globe Newswire: 22:07 GMT Wednesday 16th May 2018

Published: .

Search for other references to "therapeutics" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers